Cochlear Financial Statements From 2010 to 2025
| CHEOF Stock | USD 175.01 6.34 3.76% |
Check Cochlear financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cochlear's main balance sheet or income statement drivers, such as , as well as many indicators such as . Cochlear financial statements analysis is a perfect complement when working with Cochlear Valuation or Volatility modules.
Cochlear |
Cochlear Limited Company Operating Margin Analysis
Cochlear's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Cochlear Operating Margin | 0.23 % |
Most of Cochlear's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cochlear Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Cochlear Limited has an Operating Margin of 0.2311%. This is 100.66% lower than that of the Healthcare sector and 100.59% lower than that of the Medical Devices industry. The operating margin for all United States stocks is 104.19% lower than that of the firm.
Cochlear Limited Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cochlear's current stock value. Our valuation model uses many indicators to compare Cochlear value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cochlear competition to find correlations between indicators driving Cochlear's intrinsic value. More Info.Cochlear Limited is rated below average in return on equity category among its peers. It is number one stock in return on asset category among its peers reporting about 0.57 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Cochlear Limited is roughly 1.76 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cochlear's earnings, one of the primary drivers of an investment's value.About Cochlear Financial Statements
Cochlear stakeholders use historical fundamental indicators, such as Cochlear's revenue or net income, to determine how well the company is positioned to perform in the future. Although Cochlear investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cochlear's assets and liabilities are reflected in the revenues and expenses on Cochlear's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cochlear Limited. Please read more on our technical analysis and fundamental analysis pages.
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. The company was founded in 1981 and is headquartered in Sydney, Australia. Cochlear Ord operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 4500 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Cochlear Pink Sheet
Cochlear financial ratios help investors to determine whether Cochlear Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cochlear with respect to the benefits of owning Cochlear security.